DOCUSATE SODIUM ORAL LIQUID- docusate sodium oral liquid liquid Kesin Pharma Corporation

Docusate Sodium Oral Liquid

Active ingredient (in each 5mL)

Docusate Sodium 100 mg

Purpose

Stool Softener Laxative

Uses

- relieves of occasional constipation (irregularity)
- generally produces bowel movement in 12 to 72 hours

Warnings

Do not use

- for more than 1 week unless directed by a doctor
- if you are currently taking mineral oil, unless directed by a doctor

Ask a doctor before use if you have

- stomach pain
- nausea
- vomiting
- noticed a sudden change in bowel habits that persists over a period of 2 weeks

Stop use and ask a doctor if

- you have rectal bleeding or failure to have a bowel movement after use of a laxative. These could be signs of a serious condition.
- a skin rash occurs
- you experience throat irritation

If pregnant or breast-feeding,

ask a health professional before use.

Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center right away.

Directions

- shake well before using
- must be given in a 6 oz to 8 oz glass of milk, fruit juice or infant formula to mask the bitter taste and prevent throat irritation
- take maximum dose daily until first bowel movement, dosage should then be reduced according to individual response
- do not exceed recommended dose
- follow dosing directions below or use as directed by a doctor

1 teaspoonful = 5 mL

Age	Dose
adults and children 12 years and older	1 to 7 teaspoonfuls
children 2 to under 12 years of age	1 to 3 teaspoonfuls
children under 2 years of age	ask a doctor

Other Information

- store at controlled room temperature 20°C to 25°C (68°F to 77°F)
- protect from light
- protect from excessive heat
- protect from freezing
- clear, grape-flavored liquid, supplied in the following:

NDC 81033-022-10: 10 mL unit dose cup

NDC 81033-022-50: Case containing 100 unit dose cups of 10 mL each

Inactive ingredients

citric acid, grape flavor, methylparaben, monoammonium glycyrrhizinate, potassium citrate, propylene glycol, propylparaben, purified water, sorbitol, sucralose

Ouestions or comments?

Call 1-833-537-4679

Packaged by:

Kesin Pharma

Oldsmar, FL 34677

Rev. 04/2025



NDC 81033-022-50

Docusate Sodium Oral Liquid 100 mg/10 mL

Delivers 10 mL Case = 100 UD Cups (Do Not Break Case)

Storage: 68°F to 77°F (20°C to 25°C)

QTY: 1

NDC 81033-022-50

Product Name: Docusate Sodium Oral Liquid 100 mg/10 mL

Delivers 10 mL Case = 100 UD Cups (Do Not Break Case)

Storage: 68°F to 77°F (20°C to 25°C)

EXP: 00-APR-0000 LOT: K0000000 QTY: 1



(17) 000400 (10) K0000000 (30) 1



(01) 00381033022505



Packaged by and Distributed by: Kesin Pharma Corporation - Oldsmar, FL



DOCUSATE SODIUM ORAL LIQUID

docusate sodium oral liquid liquid

Product Information

Product Type HUMAN OTC DRUG Item Code (Source) NDC:81033-022(NDC:84447-011)

Route of Administration ORAL

Active Ingredient/Active Moiety

Ingredient Name

Basis of Strength

OCUSATE SODIUM (UNII: F05Q2T2JA0) (DOCUSATE - UNII:M7P27195AG)

DOCUSATE SODIUM

100 mg in 10 mL

Inactive Ingredients Ingredient Name Strength PROPYLENE GLYCOL (UNII: 6DC9Q167V3)

SUCRALOSE (UNII: 96K6UQ3ZD4)
POTASSIUM CITRATE (UNII: EE90ONI6FF)

SORBITOL (UNII: 506T60A25R) **GRAPE** (UNII: 6X543N684K)

PROPYLPARABEN (UNII: Z8IX2SC10H)

WATER (UNII: 059QF0KO0R)

CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)	
AMMONIUM GLYCYRRHIZATE (UNII: 3VRD35U26C)	
METHYLPARABEN (UNII: A2I8C7HI9T)	

Product Characteristics			
Color		Score	
Shape		Size	
Flavor	GRAPE	Imprint Code	
Contains			

P	Packaging			
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:81033- 022-50	100 in 1 CASE	04/01/2025	
1	NDC:81033- 022-10	10 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
OTC Monograph Drug	M007	04/01/2025	

Labeler - Kesin Pharma Corporation (117447816)

Establishment			
Name	Address	ID/FEI	Business Operations
Kesin Pharma Corporation		117447816	pack(81033-022) , label(81033-022) , repack(81033-022)

Revised: 4/2025 Kesin Pharma Corporation